Solid Biosciences Surges on DMD Gene Therapy Study Amendments

Shares of Solid Biosciences Inc. SLDB have gained 70.4% since Aug 14 as investors cheered the amendments made to a gene therapy study protocol evaluating its lead candidate, SGT-001 as a potential treatment for Duchenne muscular dystrophy (“DMD”). The company announced the update in its second-quarter earnings release.